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Abstract: In risk-stratified cancer screening, multiple risk factors are incorporated into the risk
assessment. An individual’s estimated absolute cancer risk is linked to risk categories with tailored
screening recommendations for each risk category. Absolute risk, expressed as either remaining
lifetime risk or shorter-term (five- or ten-year) risk, is estimated from the age at assessment. These risk
estimates vary by age; however, some clinical guidelines (e.g., enhanced breast cancer surveillance
guidelines) and ongoing personalised breast screening trials, stratify women based on absolute risk
thresholds that do not vary by age. We examine an alternative approach in which the risk thresholds
used for risk stratification vary by age and consider the implications of using age-independent risk
thresholds on risk stratification. We demonstrate that using an age-independent remaining lifetime
risk threshold approach could identify high-risk younger women but would miss high-risk older
women, whereas an age-independent 5-year or 10-year absolute risk threshold could miss high-risk
younger women and classify lower-risk older women as high risk. With risk misclassification, women
with an equivalent risk level would be offered a different screening plan. To mitigate these problems,
age-dependent absolute risk thresholds should be used to inform risk stratification.
J. Pers. Med. 2021, 11, 916. https://doi.org/10.3390/jpm11090916 https://www.mdpi.com/journal/jpm
J. Pers. Med. 2021, 11, 916 2 of 9
Keywords: absolute risk; remaining lifetime risk; risk threshold; risk-stratified screening;
misclassification
1. Introduction
Risk-stratified screening approaches have emerged as promising strategies to improve
the efficiency of cancer screening programmes and to reduce their adverse consequences [1–3].
A risk-stratified screening program would involve individualised risk assessment based
on a range of risk factors (e.g., genetic, lifestyle, hormonal, reproductive), partitioning
population risk into several risk categories, assigning individuals to specific risk categories,
and tailoring screening recommendations to each risk category [4]. Risk thresholds for risk
stratification are the key to translating the results of individualised risk assessment into
screening strategies [5].
Several breast cancer risk assessment models are available. These models estimate a
woman’s absolute risk of developing breast cancer, either over a fixed time horizon (e.g.,
five or ten years) or over her remaining lifetime (e.g., from current age to age 80 or 85) [6–9].
Clinical guidelines in the US [10,11] and in Canada [12] recommend enhanced breast
screening (annual mammogram and adjunctive breast MRI from young age) of women
with a lifetime risk for breast cancer of 20% (US)—25% (Canada) or over, as assessed by risk
models such as the Tyrer–Cuzick [6] or Breast and Ovarian Analysis of Disease Incidence
of Carrier Estimation Algorithm (BOADICEA) [7] risk models. However, when a woman is
referred to a high-risk clinic, her risk is assessed from her current age; hence, her remaining
lifetime risk is being estimated rather than her lifetime risk. The latter is an estimate of risk
from a fixed index age to truncated upper age, e.g., age 20 to 80 years [7]. Whilst remaining
lifetime risk of breast cancer decreases with age (Table S1), the risk stratification is based
on an absolute risk threshold that does not vary by age.
Five-year absolute risk thresholds are also used by clinical guidelines [10] and by
ongoing personalised breast cancer screening randomised trials [13,14]. For example, the
US National Comprehensive Cancer Network (NCCN) guidelines recommend annual
mammograms for women over the age of 35 whose 5-year risk of invasive breast cancer,
assessed by the modified Gail model, is 1.7% or higher [10]. In the My Personalised Breast
Screening (MyPeBS) trial, women aged 40 to 70 years recruited to the risk-based screening
arm are stratified into four risk-groups based on 5-year risk estimates: <1% (low risk),
1–1.66% (average risk), 1.67–5.99% (high risk), and ≥6% (very high risk), with the offer
of 4-yearly, 2-yearly, annual mammography, and annual mammography with adjunctive
MRI, respectively [13]. The 5-year risk is estimated from the age at recruitment to the trial.
Whilst 5-year absolute risk of breast cancer increases with age (Table S1), risk stratification
is based on absolute risk thresholds that do not vary by age.
In each of these examples, the risk thresholds do not take into account a woman’s
age at the time of risk assessment. However, since the absolute risk of breast cancer varies
substantially by age, this will have a substantial influence on the proportion of women
falling into each risk category. Here, we examine an alternative approach in which risk
thresholds vary by age, consider the implications of using age-independent risk thresholds
on risk stratification, and present age-dependent absolute risk thresholds for tailoring
screening recommendations in Canada.
2. Materials and Methods
We defined age-dependent risk thresholds based on relative risk of breast cancer,
relative to the population average. We calculated age-dependent risk thresholds (riskthreshold
(t) at age t) that are equivalent to those for a 30-year-old woman having a specified absolute
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risk, with ‘equivalence’ defined as having the same relative risk (RR) (relative to the







2.1. Calculating Age-Dependent Absolute Risk Thresholds
In order to preserve the general intent of the extant guidelines, we considered three
remaining lifetime risk categories, all from age 30 to 80 years, of <15%, 15–24% and≥25% as
‘average’, ‘higher than average’, and ‘high’ risk, respectively. The high-risk threshold from
age 30 to 80 corresponds to the definition used by the High-Risk Ontario Breast Screening
Program [15]. We calculated age-conditional absolute risk (riskpop), 5- and 10-year absolute
risk and remaining lifetime risk to age 80 for women in Canada of varying ages 30 to
79 years (Table S1), using DevCan software (version 6.7.6 US National Cancer Institute,
SA) [16] and data from Statistics Canada [17] on breast cancer incidence, mortality from
breast cancer, and mortality from other causes between 2012 to 2016.
A 30-year-old woman in Canada has a remaining lifetime risk of breast cancer of
10.1%. The 25% and 15% remaining lifetime risk thresholds at age 30 are equivalent to
relative risks of 2.7 and 1.5, respectively. Given the age-specific population absolute risk





In a sensitivity analysis, we calculated 5- and 10-year absolute risk thresholds equiva-
lent to those for a 40-year-old woman having remaining lifetime risk of 25% and 15%.
2.2. Estimating the Proportion at High Risk
The overall discriminatory ability of a breast cancer risk prediction model that in-
corporates a polygenic risk score (based on 313 breast cancer susceptibility variants) and
lifestyle, hormonal, and reproductive risk factors is estimated to have an Area Under the
Curve (AUC) of 0.65 [18]. Assuming a log-additive interaction between the risk factors,
the distribution of risk in the population is log-normal on a relative risk scale [19] with an
estimated variance (σ2) of 0.30 [20]. We set the mean as –σ2/2, so that the mean relative
risk in the population equals to unity [21]. Given the mean and variance of the log-normal
relative risk distribution, we calculated the proportion of women that would have an
absolute risk (or relative risk) greater than a given absolute risk threshold.
3. Results
3.1. Age-Dependent Absolute Risk Thresholds
Table 1 presents the 10-year absolute risk thresholds that would classify 40- to 69-year-
old women in Canada into three risk categories: ‘average’, ‘higher than average’, and ‘high’
risk. The risk categories are equivalent to remaining lifetime risk (from age 30 to 80) of
<15%, 15–24%, and ≥25%, respectively. A 40-year-old woman with a 10-year absolute risk
estimate of 3.7% would be classified as high risk, whereas a 60-year-old woman with the
same risk estimate would be classified as average risk.
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Table 1. Age-specific 10-year absolute risk thresholds for the risk categories—average, higher than
average, and high risk for women in Canada (2012–2016).
Average Risk Higher Than Average Risk High Risk
Age 10-Year Absolute Risk % 10-Year Absolute Risk % 10-Year Absolute Risk %
40 [0, 2.0) [2.0, 3.6) [3.6, )
41 [0, 2.2) [2.2, 3.8) [3.8, )
42 [0, 2.3) [2.3, 4.1) [4.1, )
43 [0, 2.5) [2.5, 4.3) [4.3, )
44 [0, 2.6) [2.6, 4.6) [4.6, )
45 [0, 2.8) [2.8, 4.8) [4.8, )
46 [0, 2.9) [2.9, 5.0) [5.0, )
47 [0, 3.0) [3.0, 5.2) [5.2, )
48 [0, 3.1) [3.1, 5.4) [5.4, )
49 [0, 3.2) [3.2, 5.6) [5.6, )
50 [0, 3.3) [3.3, 5.8) [5.8, )
51 [0, 3.4) [3.4, 6.0) [6.0, )
52 [0, 3.5) [3.5, 6.2) [6.2, )
53 [0, 3.7) [3.7, 6.4) [6.4, )
54 [0, 3.8) [3.8, 6.7) [6.7, )
55 [0, 4.0) [4.0, 7.0) [7.0, )
56 [0, 4.2) [4.2, 7.2) [7.2, )
57 [0, 4.4) [4.4, 7.6) [7.6, )
58 [0, 4.6) [4.6, 7.9) [7.9, )
59 [0, 4.8) [4.8, 8.3) [8.3, )
60 [0, 5.0) [5.0, 8.6) [8.6, )
61 [0, 5.1) [5.1, 8.9) [8.9, )
62 [0, 5.3) [5.3, 9.2) [9.2, )
63 [0, 5.5) [5.5, 9.5) [9.5, )
64 [0, 5.6) [5.6, 9.7) [9.7, )
65 [0, 5.7) [5.7, 9.9) [9.9, )
66 [0, 5.8) [5.8, 10.0) [10.0, )
67 [0, 5.8) [5.8, 10.0) [10.0, )
68 [0, 5.8) [5.8, 10.0) [10.0, )
69 [0, 5.7) [5.7, 10.0) [10.0, )
10-year absolute risk categories of average risk, higher than average risk, and high risk are set to be equal to
remaining lifetime risk from age 30 to 80 years of <15%, 15% to <25%, and ≥25%, respectively.
3.2. Implications on Risk Stratification
Figure 1 shows the age-specific absolute risk thresholds based on remaining lifetime
risk (Figure 1a) and 10-year absolute risk (Figure 1b) of breast cancer incidents, using
thresholds equivalent to a remaining lifetime risk at age 30 of 25% (high risk) and 15%
(higher than average risk). Remaining lifetime risk decreases with age. A remaining
lifetime risk threshold of 25% at age 30 years would be equivalent to remaining lifetime risk
thresholds of 20% at age 55 and 14% at age 65. If the threshold for high risk is kept constant
with age (25% remaining lifetime risk threshold applied for all ages), then a woman, for
example, aged 65 years, with a remaining lifetime risk of 14%, would be classified as
average risk, and then would not receive the enhanced screening recommended for high-
risk women. An age-independent remaining lifetime risk threshold could identify high-risk
younger women but would miss high-risk older women.
Ten-year absolute risk thresholds of 1.1% and 3.7% at ages 30 and 40 would be
equivalent to remaining lifetime risk of 25% at ages 30 and 40, respectively. An age-
independent 10-year absolute risk threshold (1.1% or 3.7% 10-year absolute risk threshold
applied for all ages) could miss high-risk younger women and classify lower-risk older
women as at high risk (Figure 1b). Similarly, an age-independent 5-year absolute risk
threshold could under-classify younger women and over-classify older women (Figure S1).
Table 2 shows the age-specific relative risk associated with different absolute risk
thresholds. Based on Ontario high-risk breast screening guidelines a woman 30 years
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of age with an RR at or above 2.7, compared to the population average risk, would be
considered at high risk. With an age-independent high-risk threshold, based on remaining
lifetime risk, a woman, for example, at age 65 would need to have an RR of ≥5.2 to be
high-risk, whereas based on 10-year absolute risk, with an RR of ≥0.3 (i.e., less than the
population average risk) would be classified as high risk.





Figure 1. Age-dependent risk thresholds based on (a) remaining lifetime risk (from current age to age 80 years) and (b) 
ten-year absolute risk for breast cancer in women in Canada (2012–2016), where risk thresholds for the ‘high risk’ (red 
line) and ‘higher than average’ (blue line) risk categories have been set at remaining lifetime risks of 25% and 15%, re-
spectively, if determined at age 30 (in (a)) and age 40 (in (b)). Risk categories: high risk (red line and above), higher than 
average risk (between the blue line and the red lines), and average risk (below the blue line). Grey dotted lines represent 
age-independent risk thresholds corresponding to 25% and 15% remaining lifetime risks (from age 30 to 80) (a) and 
10-year absolute risks of 3.7% and 2.1% when assessed at age 40 are equivalent to 25% and 15% remaining lifetime risks at 
age 40 (b). Light grey dotted lines in (b) represent 10-year absolute risks of 1.1% and 0.63% when assessed at age 30, 
which are equivalent to 25% and 15% remaining lifetime risks also at age 30, respectively. 
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thresholds. Based on Ontario high-risk breast screening guidelines a woman 30 years of 
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lifetime risk, a woman, for example, at age 65 would need to have an RR of ≥5.2 to be 
high-risk, whereas based on 10-year absolute risk, with an RR of ≥0.3 (i.e., less than the 
population average risk) would be classified as high risk. 
Table 2. Age-specific relative risks associated with age-independent and age-dependent absolute 
risk thresholds for the high-risk category compared to the population average absolute risk, using 
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(b) ten-year absolute risk for breast cancer in women in Canada (2012–2016), where risk thresholds for the ‘high risk’
(red line) and ‘higher than average’ (blue line) risk categories have been set at remaining lifetime risks of 25% and 15%,
respectively, if determined at age 30 (in (a)) and age 40 (in (b)). Risk categories: high risk (red line and above), higher than
average risk (between the blue line and the red lines), and average risk (below the blue line). Grey dotted lines represent
age-independent risk thresholds correspondi g to 25% and 15% remaining lifetime risks (from age 30 to 80) (a) and 10-year
absolute risks of 3.7% and 2.1% when assessed at age 40 are equival nt to 25% and 15% remaining lifetime risks t age 40
(b). Light grey dotted lines in (b) represent 10-year absolute risks of 1.1% and 0.63% when assessed at age 30, which are
equivalent to 25% and 15% remaining lifetime risks also at age 30, respectively.
Table 2. Age-specific relative risks associated with age-independent and age-dependent absolute risk thresholds for the
high-risk category compared to the population average absolute risk, using remaining lifetime risk and 10-year absolute
risk for breast cancer in women in Canada (2012–2016).
Remaining Lifetime Risk Metric















risk vs. populat on
average risk)
30 10.1 25.0 2.7 25.0 2.7
35 10.0 25.0 2.7 24.8 2.7
40 9.8 25.0 2.8 24.3 2.7
45 9.3 25.0 2.9 23.2 2.7
50 8.6 25.0 3.2 21.6 2.7
55 7.7 25.0 3.6 19.5 2.7
60 6.7 25.0 4.1 17.1 2.7
65 5.4 25.0 5.2 13.9 2.7
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Table 2. Cont.
10-year Absolute Risk Metric

















30 0.4 1.1 2.7 1.1 2.7
35 0.8 1.1 1.4 2.2 2.7
40 1.3 1.1 0.8 3.6 2.7
45 1.8 1.1 0.6 4.8 2.7
50 2.2 1.1 0.5 5.8 2.7
55 2.6 1.1 0.4 7.0 2.7
60 3.3 1.1 0.3 8.6 2.7
65 3.8 1.1 0.3 9.9 2.7
Relative risks calculated using Equation (1). High risk is defined as remaining lifetime risk (from age 30 to 80 years) of 25%.
Figure 2 presents the proportion of women in Canada age 30 to 69 years considered at
high risk when the log-normal distribution of risk in the population has a variance of 0.30,
and a 10-year absolute risk threshold for high risk is equivalent to a remaining lifetime risk
of 25% at age 40. With an age-dependent absolute risk threshold, even though the absolute
risk threshold increases with age, the same proportion of women, 1.8% of women, of any
age from age 30 to 69 would be classified as high risk, whereas with age-independent
absolute risk threshold, 14.4% of the women, with fewer younger women and many more
older women (over 30% of women 60 years or over), would be classified as high risk.
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4. Discussion 
Using an age-independent remaining lifetime risk threshold approach could iden-
tify high-risk younger women but would miss high-risk older women, whereas an 
age-independent 10-year or 5-year absolute risk threshold could miss high-risk younger 
women and classify lower-risk older women as high risk. Using an age-dependent ab-
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. isc ssi
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i -ris younger women but would miss hig -risk older women, whereas an age-
independent 10-year or 5-year absolute risk th eshold could miss high-risk younger women
and classify lower-risk olde women as high risk. Using an age-depend nt absolute risk
threshold for risk stratification, women with the same ab olute risk level but at differ-
ent ages could receive different screening recommendations. For example, a 40-year-old
woman with a 10-year absolute risk of breast cancer of 3.7% would be recommended
enhanced screening, whereas a 60-year-old woman with the same risk level would not.
J. Pers. Med. 2021, 11, 916 7 of 9
With risk misclassification, women with equivalent risk levels would be offered a
different screening plan. An average-risk woman, when classified as high risk, would
unnecessarily receive enhanced screening, annual mammograms, and adjunctive breast
MRI. This potentially could increase the likelihood of experiencing adverse consequences
of screening, false screening findings and overdiagnosis, as well as of inefficient use of
healthcare resources, whereas a high-risk woman missing being classified as high risk
would miss the benefits of enhanced screening.
If risk is assessed from current age, and the age at assessment varies between individ-
uals, then risk stratification with risk thresholds that are age-dependent should be used
to mitigate the problems of misclassification and inequity in provision of the screening
services. An alternative is to compute risk from a fixed index age or have a one-off risk
assessment at a particular age only in order to use age-independent absolute risk thresholds.
For example, the UK National Institute for Health and Clinical Care Excellence (NICE)
guidelines define breast cancer risk categories based on remaining lifetime risk from a fixed
index age of 20 to 80 years [22].
In the Personalized Risk Assessment for the Prevention and Early Detection of Breast
Cancer: Integration and Implementation (PERSPECTIVE I&I) study currently underway in
Canada, women aged 40 to 69 years are invited for risk assessment, and a screening plan is
proposed based on the women’s risk category, age at risk assessment, and provincial breast
screening guidelines [23]. PERSPECTIVE I&I is using age-specific 10-year risk thresh-
olds (Table 1). NICE guidelines also use age-group-specific 10-year risk categories [22].
The 5- or 10-year absolute risk estimates are better supported by evidence from empiri-
cal evaluation [24,25], less susceptible to changes in incidence and mortality rates over
time [26], better capture risk factors that change over time, and can better inform decisions
on screening start or stop ages.
In this analysis we have calculated age-dependent absolute risk thresholds equivalent
to the thresholds recommended by the clinical guidelines. The relative risk threshold
approach is a pragmatic approach to set age-dependent absolute risk thresholds. However,
evidence from empirical data is still needed to determine the absolute risk thresholds to be
used in risk-stratified breast screening programmes. In addition, evidence is needed on
whether an age-dependent, compared to age-independent, absolute risk threshold would
improve screening outcomes, such as reducing breast cancer death and overdiagnosis,
and improve the cost-effectiveness of the screening programme. Ongoing studies, such as
the PERSPECTIVE I&I, will offer evidence on the optimal risk thresholds to improve the
benefit to harm ratio and the cost-effectiveness of risk-stratified breast cancer screening
programmes, the clinical utility, and feasibility of implementing age-dependent absolute
risk thresholds for risk-stratification in breast cancer screening.
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